Michael H. Davidson - 10 Dec 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role: Director
Signature: /s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol: TENX
Transactions as of: 10 Dec 2024
Net transactions value: $0
Form type: 4
Filing time: 12 Dec 2024, 19:54:37 UTC
Previous filing: 11 Oct 2024
Next filing: 06 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TENX	Common Stock						2,881	10 Dec 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TENX	Stock Option (right to buy)	Award	$0	+100,000	$0.000000	100,000	10 Dec 2024	Common Stock	100,000	$5.94	Direct
holding	TENX	Stock Option (right to buy)					4	10 Dec 2024	Common Stock	4	$3200.00	Direct
holding	TENX	Stock Option (right to buy)					4	10 Dec 2024	Common Stock	4	$992.00	Direct
holding	TENX	Pre-Funded Warrant					47,500	10 Dec 2024	Common Stock	47,500	$0.0100	Direct	F1
holding	TENX	Warrant					25,000	10 Dec 2024	Common Stock	25,000	$4.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The pre-funded warrant has no expiration date.
F2	The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.

Content

The pre-funded warrant has no expiration date.

The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.